Shire Plans New Cinryze Versions, Promises Fresh M&A And Innovation
This article was originally published in The Pink Sheet Daily
Shire ended 2013 on a high note with promises to keep up its fast but disciplined pace to generate strong profits and cash for use in fresh drug innovation and further M&A activity.
You may also be interested in...
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.